text: Gestonorone caproate was studied in the treatment of prostate cancer in men at a dosage of 400 mg per week by intramuscular injection but, in contrast to the case of benign prostatic hyperplasia, was found to be ineffective.
  SH-834 was a combination of 90 mg estradiol valerate and 300 mg gestonorone caproate for weekly intramuscular injection that was developed by Schering in the 1960s and 1970s. It was investigated clinically as a treatment for breast cancer and was found to be effective. However, its effectiveness was found to be no better than that of an estrogen alone, and the combination was ultimately never marketed.
  Gestonorone caproate was studied by Schering for use as a progestogen-only injectable contraceptive across a dose range of 2.5 to 200 mg once every one or two months but was never marketed. There is very little clinical experience of gestonorone caproate for this indication.
  Gestonorone caproate has been studied in the treatment of ovarian cancer (in combination with cyclophosphamide), menstrual cycle-related mouth ulcers, and as a component of menopausal hormone therapy.